426 related articles for article (PubMed ID: 16697447)
1. Prognostic significance of neuroendocrine expression in lymph node-positive prostate cancer.
Quek ML; Daneshmand S; Rodrigo S; Cai J; Dorff TB; Groshen S; Skinner DG; Lieskovsky G; Pinski J
Urology; 2006 Jun; 67(6):1247-52. PubMed ID: 16697447
[TBL] [Abstract][Full Text] [Related]
2. Androgen receptor expression in prostate cancer lymph node metastases is predictive of outcome after surgery.
Sweat SD; Pacelli A; Bergstralh EJ; Slezak JM; Cheng L; Bostwick DG
J Urol; 1999 Apr; 161(4):1233-7. PubMed ID: 10081876
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of proliferation activity and neuroendocrine differentiation to predict treatment failure after radical prostatectomy.
May M; Siegsmund M; Hammermann F; Loy V; Gunia S
Scand J Urol Nephrol; 2007; 41(5):375-81. PubMed ID: 17853019
[TBL] [Abstract][Full Text] [Related]
4. Skewing towards neuroendocrine phenotype in high grade or high stage androgen-responsive primary prostate cancer.
Puccetti L; Supuran CT; Fasolo PP; Conti E; Sebastiani G; Lacquaniti S; Mandras R; Milazzo MG; Dogliani N; De Giuli P; Fasolis G
Eur Urol; 2005 Aug; 48(2):215-21; Discussion 221-3. PubMed ID: 15992991
[TBL] [Abstract][Full Text] [Related]
5. Caveolin-1 expression is a predictor of recurrence-free survival in pT2N0 prostate carcinoma diagnosed in Japanese patients.
Satoh T; Yang G; Egawa S; Addai J; Frolov A; Kuwao S; Timme TL; Baba S; Thompson TC
Cancer; 2003 Mar; 97(5):1225-33. PubMed ID: 12599229
[TBL] [Abstract][Full Text] [Related]
6. Extranodal extension in lymph node-positive prostate cancer.
Cheng L; Pisansky TM; Ramnani DM; Leibovich BC; Cheville JC; Slezak J; Bergstralh EJ; Zincke H; Bostwick DG
Mod Pathol; 2000 Feb; 13(2):113-8. PubMed ID: 10697266
[TBL] [Abstract][Full Text] [Related]
7. Glucose-regulated protein GRP78 is up-regulated in prostate cancer and correlates with recurrence and survival.
Daneshmand S; Quek ML; Lin E; Lee C; Cote RJ; Hawes D; Cai J; Groshen S; Lieskovsky G; Skinner DG; Lee AS; Pinski J
Hum Pathol; 2007 Oct; 38(10):1547-52. PubMed ID: 17640713
[TBL] [Abstract][Full Text] [Related]
8. Neuroendocrine cells in human prostate over-express the anti-apoptosis protein survivin.
Xing N; Qian J; Bostwick D; Bergstralh E; Young CY
Prostate; 2001 Jun; 48(1):7-15. PubMed ID: 11391682
[TBL] [Abstract][Full Text] [Related]
9. Transforming growth factor-beta 1: comparative immunohistochemical localization in human primary and metastatic prostate cancer.
Eastham JA; Truong LD; Rogers E; Kattan M; Flanders KC; Scardino PT; Thompson TC
Lab Invest; 1995 Nov; 73(5):628-35. PubMed ID: 7474936
[TBL] [Abstract][Full Text] [Related]
10. Long-term outcome after radical prostatectomy for patients with lymph node positive prostate cancer in the prostate specific antigen era.
Boorjian SA; Thompson RH; Siddiqui S; Bagniewski S; Bergstralh EJ; Karnes RJ; Frank I; Blute ML
J Urol; 2007 Sep; 178(3 Pt 1):864-70; discussion 870-1. PubMed ID: 17631342
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of neuroendocrine staining and androgen receptor expression in incidental prostatic adenocarcinoma: prognostic implications.
Theodoropoulos VE; Tsigka A; Mihalopoulou A; Tsoukala V; Lazaris AC; Patsouris E; Ghikonti I
Urology; 2005 Oct; 66(4):897-902. PubMed ID: 16230178
[TBL] [Abstract][Full Text] [Related]
12. The expression of neuropeptides in hyperplastic and malignant prostate tissue and its possible clinical implications.
Yu DS; Hsieh DS; Chen HI; Chang SY
J Urol; 2001 Sep; 166(3):871-5. PubMed ID: 11490236
[TBL] [Abstract][Full Text] [Related]
13. Neuroendocrine expression in node positive prostate cancer: correlation with systemic progression and patient survival.
Bostwick DG; Qian J; Pacelli A; Zincke H; Blute M; Bergstralh EJ; Slezak JM; Cheng L
J Urol; 2002 Sep; 168(3):1204-11. PubMed ID: 12187268
[TBL] [Abstract][Full Text] [Related]
14. Prognostic factors in lymph node-positive prostate cancer.
Hofer MD; Kuefer R; Huang W; Li H; Bismar TA; Perner S; Hautmann RE; Sanda MG; Gschwend JE; Rubin MA
Urology; 2006 May; 67(5):1016-21. PubMed ID: 16698361
[TBL] [Abstract][Full Text] [Related]
15. Metastatic prostate carcinoma to bone: clinical and pathologic features associated with cancer-specific survival.
Cheville JC; Tindall D; Boelter C; Jenkins R; Lohse CM; Pankratz VS; Sebo TJ; Davis B; Blute ML
Cancer; 2002 Sep; 95(5):1028-36. PubMed ID: 12209687
[TBL] [Abstract][Full Text] [Related]
16. Prediction of pelvic lymph node metastasis by the ratio of cathepsin B to stefin A in patients with prostate carcinoma.
Sinha AA; Quast BJ; Wilson MJ; Fernandes ET; Reddy PK; Ewing SL; Gleason DF
Cancer; 2002 Jun; 94(12):3141-9. PubMed ID: 12115346
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical analysis of neuroendocrine differentiation in prostate cancer.
Ishida E; Nakamura M; Shimada K; Tasaki M; Konishi N
Pathobiology; 2009; 76(1):30-8. PubMed ID: 19188748
[TBL] [Abstract][Full Text] [Related]
18. Evaluation and clinical value of neuroendocrine differentiation in human prostatic tumors.
Cussenot O; Villette JM; Cochand-Priollet B; Berthon P
Prostate Suppl; 1998; 8():43-51. PubMed ID: 9690663
[TBL] [Abstract][Full Text] [Related]
19. Oncological control after radical prostatectomy in men with clinical T3 prostate cancer: a single-centre experience.
Xylinas E; Drouin SJ; Comperat E; Vaessen C; Renard-Penna R; Misrai V; Bitker MO; Chartier-Kastler E; Richard F; Cussenot O; Roupret M
BJU Int; 2009 May; 103(9):1173-8; discussion 1178. PubMed ID: 19040530
[TBL] [Abstract][Full Text] [Related]
20. Expression of clusterin in prostate cancer correlates with Gleason score but not with prognosis in patients undergoing radical prostatectomy without neoadjuvant hormonal therapy.
Miyake H; Muramaki M; Kurahashi T; Yamanaka K; Hara I; Gleave M; Fujisawa M
Urology; 2006 Sep; 68(3):609-14. PubMed ID: 16979705
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]